| Phase 18 trials |
|
Phase 1
|
NCT03360734 |
Nov 2017 → May 2020 |
cancer |
Glycotope GmbH |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03054038 |
Jul 2017 → Mar 2022 |
non-small cell lung carcinoma |
Vanderbilt-Ingram Cancer Center |
Terminated
|
No outcome recorded
|
|
Phase 1
|
NCT02789345 |
Oct 2016 → Oct 2017 |
non-small cell lung carcinoma |
Eli Lilly and Company |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02496663 |
May 2016 → Jun 2027 expected |
non-small cell lung carcinoma |
National Cancer Institute (NCI) |
Active not recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT02451930 |
Sep 2015 → Jan 2017 |
non-small cell lung carcinoma |
Eli Lilly and Company |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02411591 |
Jun 2015 → Jun 2017 |
metastatic neoplasm, non-small cell lung carcinoma |
Eli Lilly and Company |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT01088464 |
Jan 2010 → Feb 2012 |
neoplasm |
Eli Lilly and Company |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT00801177 |
Nov 2004 → Feb 2007 |
cancer |
Eli Lilly and Company |
Completed
|
No outcome recorded
|
| Phase 1/23 trials |
|
Phase 1/2
|
NCT04285671 |
Jan 2021 → Dec 2026 expected |
non-small cell lung carcinoma |
Jonsson Comprehensive Cancer Center |
Active not recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT03387111 |
Jan 2018 → Apr 2019 |
squamous cell carcinoma |
ImmunityBio, Inc. |
Terminated
|
No outcome recorded
|
|
Phase 1/2
|
NCT01763788 |
May 2013 → Jun 2017 |
non-small cell squamous lung carcinoma |
Eli Lilly and Company |
Completed
|
No outcome recorded
|
| Phase 210 trials |
|
Phase 2
|
NCT03944772 |
Jun 2019 → May 2025 overdue |
non-small cell lung carcinoma |
AstraZeneca |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT03574818 |
May → Oct 2018 |
squamous cell lung carcinoma |
Montefiore Medical Center |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT02941601 |
Nov 2016 → Dec 2017 |
non-small cell squamous lung carcinoma |
Eli Lilly and Company |
Withdrawn
|
No outcome recorded
|
|
Phase 2
|
NCT02392507 |
Oct 2015 → Jan 2018 |
non-small cell lung carcinoma |
Eli Lilly and Company |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT02443337 |
Jul 2015 → Sep 2017 |
non-small cell lung carcinoma |
Eli Lilly and Company |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT01788566 |
Mar 2013 → Aug 2014 |
non-small cell lung carcinoma |
Eli Lilly and Company |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT01769391 |
Jan 2013 → Apr 2015 |
non-small cell squamous lung carcinoma |
Eli Lilly and Company |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT01624467 |
Aug 2012 → May 2014 |
cancer |
Eli Lilly and Company |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT01606748 |
Aug 2012 → Jun 2013 |
cancer |
Eli Lilly and Company |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT00835185 |
Aug 2007 → Jan 2010 |
colorectal cancer |
Eli Lilly and Company |
Completed
|
No outcome recorded
|
| Phase 32 trials |
|
Phase 3
|
NCT00981058 |
Jan 2010 → Jun 2013 |
non-small cell lung carcinoma |
Eli Lilly and Company |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT00982111 |
Nov 2009 → Nov 2012 |
non-small cell lung carcinoma |
Eli Lilly and Company |
Completed
|
No outcome recorded
|